A Study of OLR in First-line Treatment of Mantle Cell Lymphoma

  • End date
    Oct 15, 2023
  • participants needed
  • sponsor
    Tianjin Medical University Cancer Institute and Hospital
Updated on 19 November 2021
measurable disease
mantle cell lymphoma


This is a single-arm, multicenter, open label phase II clinical study to evaluate the efficacy and safety of OLR in the treatment of initially treated mantle cell lymphoma.


Patients initially treated with mantle cell lymphoma were screened for OLR regimen according to study admission criteria. The study will accept up to 24 cycles of treatment until disease progression or intolerable toxicity occurs and subjects voluntarily withdraw informed consent. Patients undergoing hematopoietic stem cell transplantation after complete remission may begin stem cell collection after induction therapy for at least 6 months. Twenty-nine patients are expected to be enrolled

Condition Lymphoma, Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma, Mantle cell lymphoma
Treatment Orelabrutinib in in combination of rituximab and lenalidomide(OLR)
Clinical Study IdentifierNCT05076097
SponsorTianjin Medical University Cancer Institute and Hospital
Last Modified on19 November 2021


Yes No Not Sure

Inclusion Criteria

Histopathologically confirmed mantle cell lymphoma with chromosomal translocation. All subjects must provide adequate archived or fresh tumor tissue samples for immunohistochemistry (IHC) testing
Age 18-70, both male and female
No previous systemic treatment for lymphoma
Have at least one measurable lesion. Measurable disease was defined as measurable tumor masses 1.5 cm in one or both dimensions and measurable spleen lesions
Eastern Oncology Collaboration group physical status score was 0-2
Adequate hematological function
Life expectancy >3 months
Have the ability to provide written informed consent and understand and comply with study requirements
Ability to adhere to research visit schedules and other protocol requirements

Exclusion Criteria

Histology conformed blastolytic mantle cell lymphoma and polymorphic mantle cell lymphoma
Patients with current or suspected central nervous system involvement and history of this disease
Received Bruton's tyrosine kinase inhibitor treatment
Receive lenalidomide treatment
Received other anti-tumor treatments
Major surgery within 4 weeks prior to screening
Have a history of other active malignant diseases within 2 years prior to study entry
Systemic fungal, bacterial or viral infection with uncontrolled activity
The following serological states are known for human immunodeficiency virus (HIV) infection or suggest the presence of active hepatitis B or C virus infection
Clinically serious cardiovascular disease
A history of severe hemorrhagic disorders, such as hemophilia A, hemophilia B, von willebrand disease, or A history of spontaneous bleeding requiring blood transfusion or other medical intervention
A history of deep vein thrombosis (DVT) or pulmonary embolism (PE) within the past 12 months
A history of major cerebrovascular disease/event, including stroke or intracranial hemorrhage, in the 6 months prior to first administration of the study drug
Anticoagulant therapy with warfarin or an equivalent vitamin K antagonist or anticoagulant therapy is required within 7 days of initial use of the study drug
Pregnant or lactating women
Hypersensitivity to any study drug
The presence of any life-threatening disease, medical condition, or organ system dysfunction that the investigator considers to be likely to affect the safety of the subject or cause risk
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note